Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06557057

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

Status
Recruiting
Phase
Study type
Observational
Enrollment
66 (estimated)
Sponsor
Mayo Clinic · Academic / Other
Sex
Female
Age
Healthy volunteers
Accepted

Summary

This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.

Detailed description

PRIMARY OBJECTIVE: I. Assess the impact of endocrine adjuvant therapy with aromatase inhibitors in women with hormone receptor positive breast cancer, ductal carcinoma in situ (cancer, DCIS ), or women with other high risk breast conditions, on various indices of glucose homeostasis, utilizing oral minimal model assessment, in comparison to healthy post menopausal women and another cohort of women on tamoxifen. OUTLINE: This is an observational study. Patients undergo blood sample collection, glucose testing, dual-energy x-ray absorptiometry (DEXA) scan to measure body composition, complete a questionnaire and have their medical records reviewed on study.

Conditions

Interventions

TypeNameDescription
OTHERNon-Interventional StudyNon-Interventional Study

Timeline

Start date
2023-11-16
Primary completion
2026-12-01
Completion
2026-12-01
First posted
2024-08-16
Last updated
2026-03-31

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06557057. Inclusion in this directory is not an endorsement.

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk (NCT06557057) · Clinical Trials Directory